La cadena de opciones muestra datos clave de las opciones de acciones de Precision Optics Corp a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Precision Optics Corp..

Precision Optics Corp (NASDAQ:POCI) Bolsa, Cadena de Opciones

Precision Optics Corp

Precision Optics Corp Inc is engaged in designing, developing, and manufacturing advanced optical instruments. It manufactures medical products such as endoscopes and endocouplers which incorporate various optical technologies for use in a variety of minimally invasive surgical and diagnostic procedures. The company also produces endoscopes for various applications as well as designs and manufactures custom optical medical devices to satisfy customers' specific requirements. In addition, the company manufactures and sells components and assemblies specially designed for industrial and military use. The company earns the majority of its revenue from the United States.

Precision Optics Corporation, Inc. - Common stock

Precision Optics Corp Inc

<h3>Gainers</h3>
<ul>
<li>Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) stock rose 21.4% to $4.7 during Monday's after-market session. The company's market cap stands at $35.8 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 15.01% to $0.25. The market value of their outstanding shares is at $11.0 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares rose 9.52% to $0.69. The company's market cap stands at $16.4 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares moved upwards by 8.26% to $4.06. The market value of their outstanding shares is at $2.6 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) shares moved upwards by 7.83% to $0.34. The company's market cap stands at $19.8 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock increased by 7.61% to $8.34. The market value of their outstanding shares is at $6.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares decreased by 29.9% to $0.75 during Monday's after-market session. The market value of their outstanding shares is at $7.0 million. </li>
<li>Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) stock fell 16.07% to $141.77. The company's market cap stands at $4.0 billion. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock declined by 13.67% to $0.56. The company's market cap stands at $98.4 million. </li>
<li>Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) stock declined by 12.11% to $1.38. The market value of their outstanding shares is at $9.6 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 10.42% to $0.21. The company's market cap stands at $1.3 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock decreased by 9.31% to $1.17. The market value of their outstanding shares is at $12.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BCAB

BSGM

CRIS

GOVX

HCTI

KRYS

MCRB

NAOV

NERV

POCI

VERO

YCBD

12 Health Care Stocks Moving In Monday's After-Market Session

<ul>
<li>$3.1 million of new orders received during the current calendar year</li>
<li>$6.6 million customer program backlog expected to be delivered over next 12 months
<ul>
<li>$3.9 million of additional commitments expected to be received for calendar 2026 &nbsp;</li>
</ul>
</li>
</ul>

News

Contracts

Precision Optics Enters Into Main Purchase Agreement With Aerospace Customer And Expands Program Backlog To $6.6M

Precision Optics Corporation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has entered into securities purchase agreements with institutional and accredited investors for the purchase and sale of 1,272,500 shares of the Company's common stock, par value $0.01 per share, pursuant to a registered direct offering at a purchase price of $4.00 per share, resulting in gross proceeds of approximately $5.1 million, and expected net proceeds of approximately $5.0 million after deducting offering expenses. The Company intends to use the net proceeds from the offering to repay certain indebtedness, expand its facilities to support expected growth and related general working capital purposes.
The closing of the offering, which was led by existing stockholders, is expected to occur on or about February 21, 2025, subject to the satisfaction of customary closing conditions.

Offerings

Precision Optics Prices $5.1M Offering Of 1,272,500 Shares Of Common Stock At A Price Of $4.00 Per Share

Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) reported quarterly losses of $(0.15) per share. This is a 15.38 percent decrease over losses of $(0.13) per share from the same period last year. The company reported $4.53 million in sales this quarter. This is a 6.16 percent decrease over sales of $4.82 million the same period last year.

Earnings

Precision Optics Corp Q2 EPS $(0.15) Down From $(0.13) YoY, Sales $4.53M Down From $4.82M YoY

ABNB

AENT

AGIO

ALNY

AMAT

APDN

ATUS

AVNT

BENF

BFAM

BLIN

BPMC

BRKR

BTOC

CBRE

CEVA

CLBT

CNVS

COHU

COIN

CROX

CYBR

DDOG

DKNG

DNOW

DXCM

EEFT

EGAN

ELME

ELVA

FBRT

FROG

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

IRMD

ISSC

KELYA

KELYB

KNSL

LECO

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

Precision Optics Secures Initial $340K Production Order From A Large, Global Medical Device Company For New Single-use Ophthalmic Endoscope

Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) reported quarterly losses of $(0.21) per share. This is a 162.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $4.20 million in sales this quarter. This is a 2.88 percent decrease over sales of $4.32 million the same period last year.

Precision Optics Corp Q1 EPS $(0.21) Down From $(0.08) YoY, Sales $4.20M Down From $4.32M YoY

AFMD

AGAE

AIRI

AKYA

AQMS

AREC

ASND

ASTS

AZUL

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POST

Earnings Scheduled For November 14, 2024

Biotech

General

Precision Optics Customer Receives FDA 510(k) Clearance

Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) reported quarterly losses of $(0.23) per share. This is a 1050 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $4.72 million in sales this quarter. This is a 6.13 percent decrease over sales of $5.02 million the same period last year.

Precision Optics Corp Q4 EPS $(0.23) Down From $(0.02) YoY, Sales $4.72M Down From $5.02M YoY

WIIM

Precision Optics shares are trading lower after the company announced a $1.4 million registered direct offering.

Precision Optics Prices $1.4M Registered Direct Offering

Precision Optics Corporation Inc Files For Mixed Shelf Of Up To $75M

Precision Optics Q3 2024 EPS $(0.05) Up From $(0.07) YoY; Revenue $5.242M Up From $5.048M YoY

Precision Optics Corporation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced a $9 million production order from a leading surgical company to supply single-use endoscope assemblies used in their cystoscopy surgery system. The assembly draws on POC's unique micro-optics and digital imaging technologies. This is the largest order POC has ever received and illustrates the opportunities that single-use applications provide to the Company. &nbsp;
Production deliveries are scheduled to begin July 2024 and proceed over several quarters. The Company presently estimates approximately $2.2 million in deliveries during its fiscal year ended June 2025, $4.6 million in fiscal 2026, and the remainder in the first half of fiscal 2027. Precision Optics has been performing engineering work for this customer and produced a limited number of units for testing and regulatory purposes. The Company expects a related $0.5 million order for related specialty engineering work over the next six months, bringing the total order value to approximately $9.5 million.

Precision Optics Announces Record $9M Production Order For High Volume Single-Use Cystoscopy Surgery Program; Expects A Related $0.5M Order For Related Specialty Engineering Work Over The Next Six Months, Bringing The Total Order Value To ~$9.5M

Precision Optics Wins $1.26M Follow On Production Order From Defense Company

Precision Optics Corporation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced it has received a $720,000 follow on production order from a top tier defense/aerospace company addressing a commercial application that leverages the Company's proprietary manufacturing technology developed for high precision micro-optics systems. &nbsp;
The Company received an initial $680,000 production order as of September 2023, and $517,000 in follow on production orders in November and December 2023. With today's announcement, total production orders for this leading-edge application now total more than $1.9 million. All orders currently received for this program are expected to be delivered by August 2024.
"Precision Optics continues to be at the forefront of innovation, helping yet another of the world's leading defense and aerospace companies develop next generation solutions," commented Dr. Joe Forkey, CEO of Precision Optics. "The optical assembly we developed for this program met the high-performance requirements necessary to support our customer's product, leading to multiple follow-on orders that will be delivered in the near-term. This program, coupled with others for which we have recently received manufacturing orders, gives us confidence that we will see strong sequential revenue growth throughout the remainder of fiscal year 2024. Importantly, based on customer discussions, we anticipate continuing order volumes for the next fiscal year and beyond. We believe our success here bodes well for our continued expansion efforts in the defense and aerospace market."

Precision Optics Announces Receipt Of $720,000 Follow-On Production Order From Top Tier Defense/Aerospace CustomerFfor New Optical Application

Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) reported quarterly losses of $(0.13) per share. This is a 218.18 percent decrease over earnings of $0.11 per share from the same period last year. The company reported $4.82 million in sales this quarter. This is a 18.06 percent decrease over sales of $5.89 million the same period last year.

Precision Optics Corp Q2 EPS $(0.13) Down From $0.11 YoY, Sales $4.82M Down From $5.89M YoY

Comments

Precision Optics Corp

Precision Optics Corp (POCI) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL